Lung Cancer Genomics.

Clicks: 214
ID: 12877
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #15 of 22 articles by views in acta medica academica

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The landscape of lung cancer treatment is rapidly evolving with the use of genomic testing which helps identify specific mutations or resistance mutations for these heterogenous tumors. Advanced lung cancer has a very poor prognosis but identifying other treatment options based on genomic profiling of the tumor can lead to improved outcomes. Evidence of benefit for genomic testing in lung cancer has now resulted in this test becoming part of national guidelines. There are challenges with genomic testing which need to be understood as well as understanding how to apply test results. These results can help identify treatment options or may serve as predictors to respond to specific therapies. CONCLUSION: In the current era of precision medicine, it is imperative clinicians be familiar with genomic testing and be able to offer it to their cancer patients, specifically those with advanced lung cancer.
Reference Key
parikh2019lungacta Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Parikh, Ankur R;
Journal acta medica academica
Year 2019
DOI
10.5644/ama2006-124.244
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.